Bmi-1在乳腺浸润性导管癌中的表达及临床意义

目的探讨Bmi-1在乳腺浸润性导管癌中的表达及其与临床病理特征之间的关系。方法采用免疫组织化学法检测60例乳腺浸润性导管癌组织中Bmi-1及Her-2、ER、PR的表达情况,并检测了30例乳腺增生症中Bmi-1表达情况。结果 60例乳腺浸润性导管癌中,Bmi-1蛋白高表达29例(48.3%),30例乳腺增生症中Bmi-1蛋白高表达6例(20.0%),两组之间差异有显著性(P<0.05)。Bmi-1蛋白阳性表达与乳腺浸润性导管癌的淋巴结转移及TNM分期密切相关(P<0.05),而与患者的年龄、肿瘤大小、组织学分级、Her-2、ER、PR等无显著性相关(P>0.05)。结论 Bmi-1蛋白在乳腺浸润性导管癌中的高表达与肿瘤进展相关,提示Bmi-1可能成为预测乳腺癌转移的新分子标志物。

Expression and clinical significance of Bmi-1 in breast infiltrating ductal carcinoma

Objective To investigate the expression and clinicopathologic significance of Bmi-1 in breast infiltrating ductal carcinoma.Methods Immunohistochemistry method was applied to detect the expression of Bmi-1,Her-2,ER and PR in 60 cases of breast infiltrating ductal carcinoma.And Bmi-1 was also detected in 30 cases of mammary hyperplasia.Results In 60 cases of breast infiltrating ductal carcinoma,the Bmi-1 protein was highly expressed in 29 cases（48.3%）.In 30 cases of mammary hyperplasia,the Bmi-1 protein was highly expressed in 6 cases（20.0%）,there was significant differences between the two groups（P〈0.05）.The intensive expression of Bmi-1 was positively correlated to lymph node metastasis and clinical stage（P〈0.05）,but not to age,tumor size,histological grading,Her-2,estrogen receptor（ER）,progesterone receptor（PR） expression（P〉0.05）.Conclusion The intensive expression of Bmi-1 in breast infiltrating ductal carcinoma is related to tumor progression.Bmi-1 may serve as a new molecular marker of metastasis of breast cancer.